ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Surface Chirality Enables MtlA-Dependent Antibacterial Activity and Immune Remodeling by Gold Nanoparticles.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Skin wound infections persist through a self-reinforcing "infection-inflammation" cycle that compromises tissue repair. Here, we demonstrate that surface chirality of nanomaterials serves as an independent parameter to disrupt this loop through targeted metabolic interference. Using gold nanoparticles (GNPs) as a model, we show that D-chiral GNPs (GNP-D) exhibit superior efficacy over their L-enantiomers (GNP-L) in repressing bacterial basal metabolism and impeding near-surface motility. Integration of transcriptomic profiling and molecular dynamics identifies the mannitol-specific phosphotransferase transporter MtlA as a pivotal target, where GNP-D induces enhanced structural perturbations at functional residues compared to GNP-L. In a murine infection model, GNP-D significantly reduces bacterial burden and accelerates wound closure while repolarizing the wound microenvironment from a persistent pro-inflammatory state toward a pro-resolving and regenerative phenotype. Notably, genetic ablation of mtlA abrogates the chiral bias across all metabolic and immune readouts, providing evidence that this advantage is mediated via the MtlA/PTS axis. These results establish a "chirality-membrane-protein coupling" framework for the rational design of targeted antimicrobial and immunomodulatory nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.